We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

Features Partner Sites Information LinkXpress hp
Sign In
Advertise with Us
Werfen

Download Mobile App




Simulator Helps Choose Best Refractive Surgery

By HospiMedica staff writers
Posted on 30 May 2007
An optics visual simulator could resolve the ongoing debate over which surgical laser refractive technique is best suited for a specific patient to ensure long-term visual acuity.

The crx1T adaptive optics visual simulator enables doctors to simulate the effect of various refractive techniques, in a totally non-invasive and reversible manner, and choose the optical or surgical correction that will provide the best combination of visual acuity and patient comfort. More...
In addition to replicating the outcome of refractive surgery, participants will be able to replicate the visual effects of aberrations in another's person's vision--literally seeing through some else's eyes.

In independent studies, two separate research teams used the crx1 to induce and correct for higher-order (coma, trefoil, and spherical) aberrations, in addition to correcting for regular optical defects (defocus and astigmatism). Researchers from the Federal University of São Paulo (Brazil) and the Cole Eye Institute (Cleveland, OH, USA) performed a study showing that simulating the correction of higher-order aberrations in varying degrees can help clinicians improve overall visual acuity and patient comfort when choosing between different refractive surgery techniques.

Dr. Jean Luc Nhuyen Koa, from the Clinique de la Vision (Paris, France), used the same device to perform postoperative evaluations of patients presenting above average preoperative normal and higher-order aberrations. In both cases, amelioration is based on the best visual acuity that subjects could achieve with the best possible spectacle correction versus that of simulated refractive surgery. The studies were presented at the 2007 annual meeting of the Association for Research in Vision and Ophthalmology (ARVO), held in Ft. Lauderdale (FL, USA) during May 2007. The crx1T is made by Imagine Eyes (Orsay, France).

The implication for patients could be increased confidence in the ability of ophthalmologists to choose the safest surgical technique possible, and thus an increased willingness to undergo laser surgery.


Related Links:
Federal University of São Paulo
Clinique de la Vision
Imagine Eyes

Gold Member
POC Blood Gas Analyzer
Stat Profile Prime Plus
Antipsychotic TDM Assays
Saladax Antipsychotic Assays
Endoscopy Display
E190
Hemostatic Agent
HEMOBLAST Bellows
Read the full article by registering today, it's FREE! It's Free!
Register now for FREE to HospiMedica.com and get access to news and events that shape the world of Hospital Medicine.
  • Free digital version edition of HospiMedica International sent by email on regular basis
  • Free print version of HospiMedica International magazine (available only outside USA and Canada).
  • Free and unlimited access to back issues of HospiMedica International in digital format
  • Free HospiMedica International Newsletter sent every week containing the latest news
  • Free breaking news sent via email
  • Free access to Events Calendar
  • Free access to LinkXpress new product services
  • REGISTRATION IS FREE AND EASY!
Click here to Register








Channels

Critical Care

view channel
Image: The researchers grew pancreatic tissue (above) so it incorporated a mesh-like electronic network (red). Cells within the tissue produce insulin (green). (Photo courtesy of Penn Medicine)

‘Cyborg’ Transplants Could Replace Pancreatic Tissue Damaged by Diabetes

Type 1 diabetes destroys insulin-producing islet cells, forcing patients to rely on lifelong insulin therapy or scarce organ transplants. Although lab-grown pancreatic tissue offers a promising alternative,... Read more

Patient Care

view channel
Image: The revolutionary automatic IV-Line flushing device set for launch in the EU and US in 2026 (Photo courtesy of Droplet IV)

Revolutionary Automatic IV-Line Flushing Device to Enhance Infusion Care

More than 80% of in-hospital patients receive intravenous (IV) therapy. Every dose of IV medicine delivered in a small volume (<250 mL) infusion bag should be followed by subsequent flushing to ensure... Read more

Business

view channel
Image: Medtronic’s intent to acquire CathWorks follows a 2022 strategic partnership with a co-promotion agreement for the FFRangio System (Photo courtesy of CathWorks)

Medtronic to Acquire Coronary Artery Medtech Company CathWorks

Medtronic plc (Galway, Ireland) has announced that it will exercise its option to acquire CathWorks (Kfar Saba, Israel), a privately held medical device company, which aims to transform how coronary artery... Read more
Copyright © 2000-2026 Globetech Media. All rights reserved.